| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Purity: =99.53%
| Targets |
Deslorelin Acetate targets the gonadotropin-releasing hormone receptor (GnRHR). As a GnRH superagonist, it binds to and activates the GnRH receptor, leading to an initial stimulation of gonadotropin release. With continued administration, it causes downregulation of the receptor, resulting in suppression of sex hormone production.
|
|---|---|
| ln Vitro |
In vitro, Deslorelin Acetate is a potent GnRH agonist. It is used in cell-based assays to study GnRH receptor signaling and the regulation of gonadotropin secretion. Its activity is related to its ability to bind to and activate the GnRH receptor.
|
| ln Vivo |
In vivo, Deslorelin Acetate is used in veterinary medicine to control estrus and fertility in animals, including dogs, cats, and horses. It is also used in the treatment of precocious puberty. Research on this compound explores its applications in assisted reproductive technologies and wildlife contraception.
|
| Enzyme Assay |
In vitro receptor binding assays for Deslorelin Acetate typically involve measuring its affinity for the GnRH receptor. The compound is incubated with cells expressing the receptor, and binding is quantified. Functional assays, such as measuring gonadotropin release upon receptor activation, are also used to confirm its agonistic activity.
|
| Cell Assay |
Cell culture protocols for Deslorelin Acetate involve treating pituitary cells or cells expressing the GnRH receptor with the compound at varying concentrations. The effects on gonadotropin secretion and cell signaling are then assessed. The peptide is dissolved in a suitable solvent and added to the culture medium.
|
| Animal Protocol |
In vivo animal study protocols for Deslorelin Acetate involve its administration to animals to study its effects on reproduction. It is commonly used in veterinary medicine for estrus control and ovulation induction. In research, it is used to study the hypothalamic-pituitary-gonadal axis and reproductive function.
|
| ADME/Pharmacokinetics |
Deslorelin Acetate has a molecular weight of 1342.53 g/mol and a formula of C66H87N17O14. It has a CAS number of 82318-06-7. It is typically stored as a powder at -20°C. It is soluble in aqueous solutions and is available with high purity.
|
| Toxicity/Toxicokinetics |
Toxicological data for Deslorelin Acetate is not extensively reported in the provided sources. As a veterinary therapeutic agent, its safety profile has been established in animals. Standard safety precautions should be observed in research settings.
|
| Additional Infomation |
Deslorelin acetate is a synthetic nonapeptide natural gonadotropin-releasing hormone (GnRH) analog with potential antitumor activity. Deslorelin binds to and activates pituitary GnRH receptors. In males, sustained, long-term use of goserelin leads to pituitary GnRH receptor desensitization and inhibits the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby significantly reducing testosterone levels; in females, long-term use leads to decreased estradiol levels. (NCI04)
See also: Deslorelin (containing the active ingredient); Deslorelin; Deslorelin acetate (ingredient). Pharmaceutical Indications For inducing temporary infertility in healthy, unsterilized, sexually mature male dogs and ferrets. Deslorelin Acetate has a CAS number of 82318-06-7. It is a synthetic GnRH superagonist used in veterinary medicine for reproductive management. It has potential antitumor activity and is also used in research on assisted reproductive technologies and wildlife conservation. |
| Molecular Formula |
C64H83N17O12.C2H4O2
|
|---|---|
| Molecular Weight |
1342.50248
|
| Exact Mass |
1341.661
|
| CAS # |
82318-06-7
|
| Related CAS # |
57773-65-6;82318-06-7 (acetate);1642579-30-3;
|
| PubChem CID |
25077533
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
97
|
| Complexity |
2640
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CCNC([C@H]1CCCN1C([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]2CCC(N2)=O)=O)CC3=CN=CN3)=O)CC4=CNC5=CC=CC=C45)=O)CO)=O)CC6=CC=C(O)C=C6)=O)CC7=CNC8=CC=CC=C78)=O)CC(C)C)=O)CCCNC(N)=N)=O)=O.CC(O)=O
|
| InChi Key |
LYCYLGFSIXIXAB-NUZRHMIVSA-N
|
| InChi Code |
InChI=1S/C64H83N17O12.C2H4O2/c1-4-68-62(92)53-16-10-24-81(53)63(93)46(15-9-23-69-64(65)66)74-56(86)47(25-35(2)3)75-58(88)49(27-37-30-70-43-13-7-5-11-41(37)43)77-57(87)48(26-36-17-19-40(83)20-18-36)76-61(91)52(33-82)80-59(89)50(28-38-31-71-44-14-8-6-12-42(38)44)78-60(90)51(29-39-32-67-34-72-39)79-55(85)45-21-22-54(84)73-45;1-2(3)4/h5-8,11-14,17-20,30-32,34-35,45-53,70-71,82-83H,4,9-10,15-16,21-29,33H2,1-3H3,(H,67,72)(H,68,92)(H,73,84)(H,74,86)(H,75,88)(H,76,91)(H,77,87)(H,78,90)(H,79,85)(H,80,89)(H4,65,66,69);1H3,(H,3,4)/t45-,46-,47-,48-,49+,50-,51-,52-,53-;/m0./s1
|
| Chemical Name |
acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7449 mL | 3.7244 mL | 7.4488 mL | |
| 5 mM | 0.1490 mL | 0.7449 mL | 1.4898 mL | |
| 10 mM | 0.0745 mL | 0.3724 mL | 0.7449 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA